Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response
Abstract Body composition is an important predictor in cancer patients, with skeletal muscle loss and high adiposity associated with poorer prognosis. This study evaluated how body composition affects treatment efficacy in 48 women with metastatic breast cancer receiving trastuzumab deruxtecan. Usin...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-025-00754-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849709672040235008 |
|---|---|
| author | Shiran Yaacobi Peretz Rivka Kessner Yael Bar Amir Sonnenblick Shir Lerner Ariella Deutsch-Lukatsky Karteek Popuri Mirza Faisal Beg Shlomit Strulov Shachar |
| author_facet | Shiran Yaacobi Peretz Rivka Kessner Yael Bar Amir Sonnenblick Shir Lerner Ariella Deutsch-Lukatsky Karteek Popuri Mirza Faisal Beg Shlomit Strulov Shachar |
| author_sort | Shiran Yaacobi Peretz |
| collection | DOAJ |
| description | Abstract Body composition is an important predictor in cancer patients, with skeletal muscle loss and high adiposity associated with poorer prognosis. This study evaluated how body composition affects treatment efficacy in 48 women with metastatic breast cancer receiving trastuzumab deruxtecan. Using computed tomography, skeletal muscle, visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were assessed within 60 days before initiating treatment. High SAT and VAT areas were significantly associated with a higher likelihood of dose reductions (Odds Ratio [OR] = 5.34, p = .032 and OR = 5.52, p = 0.032, respectively). Higher SAT areas correlated with a lower objective response rate (OR = 0.22, p = 0.047). Medium SAT and low/medium VAT densities increased the risk of dose reductions. A body mass index over 25 kg/m2 was linked to higher dose reductions (OR = 4.97, p = 0.016). These findings emphasize the need for personalized treatment strategies based on body composition. |
| format | Article |
| id | doaj-art-a85f47552a8346cdae3cf85b296e6c0b |
| institution | DOAJ |
| issn | 2374-4677 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj-art-a85f47552a8346cdae3cf85b296e6c0b2025-08-20T03:15:12ZengNature Portfolionpj Breast Cancer2374-46772025-04-011111610.1038/s41523-025-00754-7Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and responseShiran Yaacobi Peretz0Rivka Kessner1Yael Bar2Amir Sonnenblick3Shir Lerner4Ariella Deutsch-Lukatsky5Karteek Popuri6Mirza Faisal Beg7Shlomit Strulov Shachar8Oncology Department, Tel Aviv Sourasky Medical CenterFaculty of Medical & Health Sciences, Tel Aviv UniversityOncology Department, Tel Aviv Sourasky Medical CenterOncology Department, Tel Aviv Sourasky Medical CenterOncology Department, Tel Aviv Sourasky Medical CenterOncology Department, Tel Aviv Sourasky Medical CenterComputer Science Department, Memorial University of NewfoundlandSchool of Engineering Science, Simon Fraser UniversityOncology Department, Tel Aviv Sourasky Medical CenterAbstract Body composition is an important predictor in cancer patients, with skeletal muscle loss and high adiposity associated with poorer prognosis. This study evaluated how body composition affects treatment efficacy in 48 women with metastatic breast cancer receiving trastuzumab deruxtecan. Using computed tomography, skeletal muscle, visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were assessed within 60 days before initiating treatment. High SAT and VAT areas were significantly associated with a higher likelihood of dose reductions (Odds Ratio [OR] = 5.34, p = .032 and OR = 5.52, p = 0.032, respectively). Higher SAT areas correlated with a lower objective response rate (OR = 0.22, p = 0.047). Medium SAT and low/medium VAT densities increased the risk of dose reductions. A body mass index over 25 kg/m2 was linked to higher dose reductions (OR = 4.97, p = 0.016). These findings emphasize the need for personalized treatment strategies based on body composition.https://doi.org/10.1038/s41523-025-00754-7 |
| spellingShingle | Shiran Yaacobi Peretz Rivka Kessner Yael Bar Amir Sonnenblick Shir Lerner Ariella Deutsch-Lukatsky Karteek Popuri Mirza Faisal Beg Shlomit Strulov Shachar Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response npj Breast Cancer |
| title | Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response |
| title_full | Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response |
| title_fullStr | Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response |
| title_full_unstemmed | Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response |
| title_short | Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response |
| title_sort | body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response |
| url | https://doi.org/10.1038/s41523-025-00754-7 |
| work_keys_str_mv | AT shiranyaacobiperetz bodycompositionmetricsasadeterminantoftrastuzumabderuxtecanrelatedtoxicityandresponse AT rivkakessner bodycompositionmetricsasadeterminantoftrastuzumabderuxtecanrelatedtoxicityandresponse AT yaelbar bodycompositionmetricsasadeterminantoftrastuzumabderuxtecanrelatedtoxicityandresponse AT amirsonnenblick bodycompositionmetricsasadeterminantoftrastuzumabderuxtecanrelatedtoxicityandresponse AT shirlerner bodycompositionmetricsasadeterminantoftrastuzumabderuxtecanrelatedtoxicityandresponse AT arielladeutschlukatsky bodycompositionmetricsasadeterminantoftrastuzumabderuxtecanrelatedtoxicityandresponse AT karteekpopuri bodycompositionmetricsasadeterminantoftrastuzumabderuxtecanrelatedtoxicityandresponse AT mirzafaisalbeg bodycompositionmetricsasadeterminantoftrastuzumabderuxtecanrelatedtoxicityandresponse AT shlomitstrulovshachar bodycompositionmetricsasadeterminantoftrastuzumabderuxtecanrelatedtoxicityandresponse |